Thermo Fisher Scientific Trading Volume Drops 24 Percent to 90th Position Despite Stock Gains

On June 20, 2025, Thermo Fisher Scientific (TMO) experienced a significant decline in trading volume, with a total of $856 million in shares traded, marking a 24.23% decrease from the previous day. This decline placed TMO at the 90th position in terms of trading volume for the day. Despite this, the stock managed to close with a 1.32% increase, marking its second consecutive day of gains and a total increase of 1.92% over the past two days.

Thermo Fisher Scientific has announced plans to sell its diagnostics unit for approximately $4 billion. This strategic move aims to divest some of its lower-growth assets, potentially streamlining its portfolio and focusing on more profitable segments.

Thermo Fisher Scientific's Accelerator™ Drug Development 360° CDMO and CRO Solutions have been highlighted in a study by the Tufts Center for the Study of Drug Development. The study demonstrated significant time savings in delivering therapies to patients, underscoring the company's commitment to innovation and efficiency in the biotech and pharmaceutical sectors.

Analysts have expressed a generally positive outlook on TMO stock, with 42% recommending a strong buy and 44% suggesting a buy. Only 14% of analysts advise holding the stock, while none recommend selling or strongly selling. This consensus reflects confidence in the company's growth prospects and financial performance.

Thermo Fisher Scientific reported Q1 2025 earnings per share (EPS) of $5.15, surpassing estimates of $5.10 by 0.98%. This performance indicates strong financial health and operational efficiency, further bolstering investor confidence in the company's future prospects.